Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Kaori Kadoyama1, Akiko Kuwahara2, Motohiro Yamamori2, JB Brown1, Toshiyuki Sakaeda1* and Yasushi Okuno1,3*

Abstract

Background: Previously, adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) database were reviewed to confirm platinum agent-associated hypersensitivity reactions. The present study was performed to confirm whether the database could suggest the hypersensitivity reactions caused by anticancer agents, paclitaxel, docetaxel, procarbazine, asparaginase, teniposide, and etoposide.

Methods: After a revision of arbitrary drug names and the deletion of duplicated submissions, AERs involving candidate agents were analyzed. The National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 was applied to evaluate the susceptibility to hypersensitivity reactions, and standardized official pharmacovigilance tools were used for quantitative detection of signals, i.e., drug-associated adverse events, including the proportional reporting ratio, the reporting odds ratio, the information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean.

Results: Based on 1,644,220 AERs from 2004 to 2009, the signals were detected for paclitaxel-associated mild, severe, and lethal hypersensitivity reactions, and docetaxel-associated lethal reactions. However, the total number of adverse events occurring with procarbazine, asparaginase, teniposide, or etoposide was not large enough to detect signals.

Conclusions: The FDA’s adverse event reporting system, AERS, and the data mining methods used herein are useful for confirming drug-associated adverse events, but the number of co-occurrences is an important factor in signal detection.

Background

Hypersensitivity reactions (HSRs), though rare in response to anticancer agents, are caused by certain classes of agents including platinum agents (cisplatin, carboplatin, and oxaliplatin), taxanes (paclitaxel and docetaxel), procarbazine and asparaginase, and epipodophyllotoxins (teniposide and etoposide) [1-5]. Despite comparatively lower frequency, doxorubicin and 6-mercaptopurine are also recognized as infrequent contributors to HSRs, and additionally other agents, e.g., 5-fluorouracil, cyclophosphamide and cytarabine, are thought to be agents that can potentially result in HSRs [1,3]. The use of the term “hypersensitivity” is widely used in clinical reports, though its use is also sporadic, and no exact definition is provided. It includes a wide array of symptoms from mild flushing and itching to lethal anaphylaxis. The pathogenic mechanisms by which the reactions occur are still unclear, although they seem to vary widely among agents. The exact prevalence of these reactions is difficult to evaluate, and such a problem is hindering the establishment of treatments.

Previously, pharmacoepidemiological studies have been conducted to confirm that adverse events have accompanied the use of cisplatin, carboplatin, and oxaliplatin [6,7]. More than a million case reports on adverse events (AERs) submitted to the US Food and Drug Administration (FDA) database were used, and a statistically significant association with an adverse event was detected as a signal, by applying standardized official...
Methods

Data sources

Input data for this study were taken from the public release of the FDA’s AERS database, which covers the period from the first quarter of 2004 through the end of 2009. The data structure of AERS is in compliance with international safety reporting guidance, ICH E2B, consisting of 7 data sets; patient demographic and administrative information (DEMO), drug/biologic information (DRUG), adverse events (REAC), patient outcomes (OUTC), report sources (RPSR), drug therapy start and end dates (THER), and indications for use/diagnosis (INDI). The adverse events in REAC are coded using preferred terms (PTs) in the Medical Dictionary for Regulatory Activities (MedDRA) terminology.

Prior to analysis, all drug names were unified into generic names by a text-mining approach, because AERS permits the registering of arbitrary drug names, including trade names and abbreviations. Spelling errors were detected by GNU Aspell and carefully confirmed by working pharmacists. Foods, beverages, treatments (e.g. X-ray radiation), and unspecified names (e.g., beta-blockers) were omitted for this study. Duplicated reports were deleted according to FDA’s recommendation of adopting the most recent CASE number, resulting in the reduction of the number of AERs from 2,231,029 to 1,644,220. The primary and secondary suspected drugs were subjected to investigation as well as concomitant drugs.

Definition of adverse events

According to the NCI-CTCAE version 4.0, AERs with PT10002198/acute allergic reaction and LLT10000663/acute anaphylactic reaction and LLT10002218/anaphylaxis. AERs both with PT10002198/hypersensitivity, and with PT10001718/death or death terms in OUTC were adopted as the reports on severe HSRs. Of note, LLT10000663/hypersensitivity reaction and LLT10002218/anaphylaxis. AERs both with PT10002198/hypersensitivity, and with PT10001718/death or death terms in OUTC were adopted as the reports on lethal HSRs. Of note, LLT10000663/hypersensitivity reaction and LLT10002218/anaphylaxis are also respectively assigned as allergic reactions and anaphylaxis in the NCI-CTCAE version 4.0, and PTs in their higher levels were used in this study.

Data mining

In pharmacovigilance analysis, data mining algorithms have been developed to identify drug-associated adverse events as signals that are reported more frequently than expected by estimating expected reporting frequencies on the basis of information on all drugs and all events in the database [12-14]. For example, the proportional reporting ratio (PRR) [8], the reporting odds ratio (ROR) [9], the information component (IC) [10], and the empirical Bayes geometric mean (EBGM) [11] are widely used, and indeed, the PRR is currently used by the Medicines and Healthcare products Regulatory Agency (MHRA), UK, the ROR by the Netherlands Pharmacovigilance Centre, the IC by the World Health Organization (WHO), and the EBGM by the FDA.

All of these algorithms extract decision rules for signal detection and/or calculate scores to measure the associations between drugs and adverse events from a two-by-two frequency table of counts that involve the presence or absence of a particular drug and a particular event occurring in case reports. These algorithms, however, differ from one another in that the PRR and ROR are frequentist (non-Bayesian), whereas the IC and EBGM are Bayesian. In this section, only the scoring thresholds used in the present study are given, and the reader is referred to review articles for more extensive details of each statistical test [12-14].
Here, we define how a drug and associated adverse event is classified as a signal when using each statistical test. Using the PRR, a drug-event pair is classified as a signal if the event count ≥ 3 and the PRR ≥ 2.0 with an associated $\chi^2$ value ≥ 4.0 [8]. Using the ROR, a signal is detected if the lower bound of the 95% two-sided confidence interval (CI) exceeds 1 [9]. Signal detection using the IC is done using the IC025 metric, a criterion indicating the lower bound of the 95% two-sided CI of the IC, and a signal is detected with the IC025 value exceeds 0 [10]. Finally, the EB05 metric, a lower one-sided 95% confidence limit of EBGM [11], is used and a signal is detected when EB05 is greater than or equal to the threshold value 2.0.

**Results**

Table 1 lists the total number of adverse events occurring with each anticancer agent we investigated, and therein the numbers of co-occurrences with mild, severe or lethal HSRs. The total number of adverse events was less than 10,000 for procarbazine, asparaginase, teniposide, and 6-mercaptopurine, and those occurring with HSRs did not exceed 30 in total per agent. For etoposide and cytarabine, about 30,000 adverse events were found in total, but the number of HSRs co-occurrences counted was only about 50.

The statistical data on 5 other agents, paclitaxel, docetaxel, doxorubicin, 5-fluorouracil, and cyclophosphamide, are summarized in Tables 2, 3 and 4. As shown in Table 2, the signals were detected for paclitaxel- and 5-fluorouracil-associated mild HSRs with 228 and 108 co-occurrences, respectively, but the association was only marginal for the latter. No signals were detected for docetaxel, doxorubicin, and cyclophosphamide. As for severe reaction, the signal was detected for paclitaxel, but no signals for other four (Table 3). The associations with lethal reactions were detected for paclitaxel, docetaxel and 5-fluorouracil (Table 4).

### Table 1 The number of adverse events occurring with each anticancer agent

| Anticancer Agent | N | Mild | Severe | Lethal |
|------------------|---|------|--------|--------|
| paclitaxel       | 42,038 | 228 * | 79 * | 12 * |
| docetaxel        | 36,983 | 79 | 18 | 17 * |
| procarbazine     | 1,287 | 1 | 0 | 0 |
| asparaginase     | 6,414 | 1 | 5 | 2 |
| teniposide       | 151 | 1 | 0 | 0 |
| etoposide        | 28,264 | 31 | 25 | 3 |
| doxorubicin      | 47,834 | 101 | 41 | 9 |
| 6-mercaptopurine | 9,170 | 17 | 13 | 0 |
| 5-fluorouracil   | 40,282 | 108 * | 44 | 10 * |
| cyclophosphamide | 70,728 | 110 | 51 | 9 |
| cytarabine       | 31,765 | 20 | 24 | 3 |

- **N**: The total number of adverse events occurring with each anticancer agent.
- **Mild**: The number of co-occurrences of mild reactions.
- **Severe**: The number of co-occurrences of severe reactions.
- **Lethal**: The number of co-occurrences of lethal reactions.
- *: A signal was detected by at least 1 of 4 statistical indices.

### Discussion

The AERS database covers several million case reports on adverse events. Pharmacovigilance analysis aims to search for previously unknown patterns and automatically detect important signals, i.e., drug-associated adverse events, from such a large database. Recently developed data mining tools for pharmacovigilance have been successful at detecting signals that could not be found by individual case reviews and that warrant further investigation together with continuous surveillance. For this reason, data mining tools are being routinely used for pharmacovigilance, supporting signal detection and decision-making at companies, regulatory agencies, and pharmacovigilance centers [8-14]. Despite some limitations inherent to spontaneous reporting, the AERS database is a rich resource and the data mining tools provide a powerful means of identifying potential associations between drugs and adverse events.

Although HSRs are considered uncommon during treatment with anticancer agents, platinum agents, taxanes, procarbazine, asparaginase, and epipodophyllotoxins are thought to increase the susceptibility to such reactions [1-5]. Previously [7], and in this study, pharmacoepidemiological analyses were performed to confirm the HSRs caused by these agents, using more than a million AERs submitted to the FDA. The NCI-CTCAE version 4.0 was applied to evaluate the susceptibility to HSRs. Carboplatin, oxaliplatin, and paclitaxel were statistically demonstrated to be associated with mild, severe, and lethal HSRs, and docetaxel was associated with lethal reactions. No signals were detected for cisplatin, procarbazine, asparaginase, teniposide, and etoposide. For these latter agents, the total number of co-occurrences with HSRs was less than 100. Although the application of the NCI-CTCAE version 4.0 might have the effect on reproducibility of clinical observations, the total number of adverse events occurring with each anticancer agent we investigated and the number of co-occurrences of HSRs would be important factors.

In this study, we tried to evaluate the demographic effect on the susceptibility to severe HSRs. The ratio of male/female/unknown was 22/49/8 for the patients with paclitaxel-related severe HSR and the average value of age was 57.4 ± 15.0 years. These values were not different from those for all AERs. Similarly to paclitaxel, we could not figure out the effects of gender or age, in the cases of docetaxel and 5-fluorouracil. Additionally, the total number of drugs co-administered with 5-fluorouracil was 211 in 44 co-occurrences, and 29 of 211 was oxaliplatin, which is a well-established cause of HSRs.
The co-administration drugs also can be confounding factor, and further analysis should be done with much larger numbers of co-occurrences.

Taxanes show poor water solubility, and are formulated with low molecular weight surfactants, for example, Cremophor EL and Tween 80 (polysorbate 80). These surfactants might contribute to HSRs. Although it is still controversial whether the surfactants or taxane moiety is responsible for HSRs [3,4,15-17], the difference between paclitaxel and docetaxel with regard to susceptibility might be explained by the surfactants [3,4]. Recently, surfactant-free novel derivatives and formulations have been developed. Their safety profiles will shed light on the debate about taxane-associated HSRs.

5-Fluorouracil, generally, is considered to be rarely associated with HSRs, although there are scattered reports of anaphylactic reactions occurring during or after its intravenous administration [18-21]. However, in this analysis, signals were detected for mild and lethal HSRs, and the susceptibility was comparable with that of docetaxel (Tables 2 and 4). This might be explained by co-administered oxaliplatin as stated. 5-Fluorouracil is used for cutaneous diseases such as psoriasis and actinic keratoses, and an irritant contact dermatitis is frequently seen [22-25]. This might be counted as hypersensitivity. Furthermore, hand-foot syndrome, a major adverse event of 5-fluorouracil, is characterized by painful erythematous lesions which mainly affect palmar-plantar surfaces [26-28]. This syndrome might affect analysis, because professionals could easily recognize symptoms involving sweat-associated toxicity, which is not a HSR, yet non-professionals might be mislead to classify the symptom as a HSR.

## Conclusions

AERs submitted to the FDA were analyzed using statistical techniques to establish the anticancer agent-associated HSRs. Based on 1,644,220 AERs from 2004 to 2009, the signals were detected for paclitaxel-associated mild, severe, and lethal HSRs, and docetaxel-associated

### Table 2 Signal detection for anticancer agent-associated mild hypersensitivity reactions

| Anticancer Agent | N  | PRR (χ²) | ROR (95% two-sided CI) | IC (95% two-sided CI) | EBGM (95% one-sided CI) |
|------------------|----|----------|------------------------|-----------------------|-------------------------|
| Paclitaxel       | 228| 2.768 *  (254.835) | 2.788 * (2.438, 3.117) | 1.450 * (1.262, 1.638) | 2.707 * (2.423) |
| Docetaxel        | 79 | 1.087 (0.463)    | 1.087 (0.871, 1.302)   | 0.109 (-0.209, 0.427)  | 1.073 (0.890)  |
| Doxorubicin      | 101| 1.074 (0.445)    | 1.074 (0.884, 1.265)   | 0.095 (-0.187, 0.376)  | 1.064 (0.902)  |
| 5-Fluorouracil   | 108| 1.365 (1.054)    | 1.366 * (1.130, 1.601) | 0.436 * (0.164, 0.708) | 1.344 (1.145)  |
| Cyclophosphamide | 110| 0.791 (0.894)    | 0.790 (0.655, 0.925)   | -0.342 (-0.612, -0.073) | 0.788 (0.673)  |

The total number of co-occurrences with mild hypersensitivity reactions was 43,288.

N: the number of co-occurrences of each anticancer agent out of 43,288 pairs, PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean.

*: signal detected, see “Methods” for the detection criteria.

### Table 3 Signal detection for anticancer agent-associated severe hypersensitivity reactions

| Anticancer Agent | N  | PRR (χ²) | ROR (95% two-sided CI) | IC (95% two-sided CI) | EBGM (95% one-sided CI) |
|------------------|----|----------|------------------------|-----------------------|-------------------------|
| Paclitaxel       | 79 | 2.273 *  (55.041) | 2.278 * (1.826, 2.730) | 1.151 * (0.833, 1.469) | 2.174 (1.803) |
| Docetaxel        | 18 | 0.588 (4.805)    | 0.587 (0.370, 0.805)   | -0.773 (-1.431, -0.115) | 0.591 (0.401) |
| Doxorubicin      | 41 | 1.036 (0.021)    | 1.036 (0.762, 1.309)   | 0.032 (-0.408, 0.471)  | 1.014 (0.782) |
| 5-Fluorouracil   | 44 | 1.320 (3.102)    | 1.321 (0.982, 1.659)   | 0.374 (-0.051, 0.799)  | 1.276 (0.994) |
| Cyclophosphamide | 51 | 0.871 (0.851)    | 0.871 (0.661, 1.080)   | -0.209 (-0.604, 0.185) | 0.862 (0.683) |

The total number of co-occurrences with severe hypersensitivity reactions was 18,255.

N: the number of co-occurrences of each anticancer agent out of 18,255 pairs, PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean.

*: signal detected, see “Methods” for the detection criteria.
Table 4 Signal detection for anticancer agent-associated lethal hypersensitivity reactions

| Anticancer Agent | N  | PRR (χ²) | ROR (95% two-sided CI) | IC (95% two-sided CI) | EBGM (95% one-sided CI) |
|------------------|----|----------|------------------------|-----------------------|------------------------|
| Paclitaxel       | 12 | 2.623 * (10.495) | 2.631 * (1.492, 3.770) | 1.165 * (0.563, 1.967) | 1.992 (1.237) |
| Docetaxel        | 17 | 4.224 * (38.715) | 4.247 * (2.635, 5.858) | 1.800 * (1.121, 2.478) | 3.268 * (2.062) |
| Doxorubicin      | 9  | 1.728 (2.086)   | 1.731 (0.900, 2.563)   | 0.614 (-0.305, 1.533)  | 1.401 (0.819)  |
| 5-Fluorouracil   | 10 | 2.281 * (5.977) | 2.286 * (1.228, 3.344) | 0.964 * (0.089, 1.838) | 1.735 (1.037)  |
| Cyclophosphamide | 9  | 1.169 (0.083)   | 1.170 (0.608, 1.731)   | 0.127 (-0.792, 1.046)  | 1.047 (0.613)  |

The total number of co-occurrences with lethal hypersensitivity reactions was 2,397.

N: the number of co-occurrences of each anticancer agent out of 2,397 pairs, PRR: the proportional reporting ratio, ROR: the reporting odds ratio, IC: the information component, EBGM: the empirical Bayes geometric mean.

*: signal detected, see "Methods" for the detection criteria.

lethal reactions. However, the total number of adverse events occurring with procarbazine, asparaginase, teniposide, or etoposide was not large enough to detect signals. The database and the data mining methods used herein are useful, but the number of co-occurrences is an important factor in signal detection.

Acknowledgements
This work was supported in part by Funding Program for Next Generation World-Leading Researchers and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author details
1Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan. 2School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya 663-8179, Japan. 3Kyoto Constella Technologies Co Ltd., Kyoto 604-8156, Japan.

Authors’ contributions
KK, AK, MY, and TS made conception, designed and coordinated the study. YO and JB carried out calculations and statistical analysis. KK, JB and TS prepared the manuscript. All authors read and approved the final manuscript.

Competing interests
The author declares that they have no competing interests.

Received: 8 August 2011 Accepted: 5 October 2011 Published: 5 October 2011

References
1. Pagani M: The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization. Med Clin North Am 2010, 94:835-852.
2. Syrigou E, Syrigos K, Safi MW: Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008, 8:56-62.
3. Shepherd GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003, 24:253-262.
4. Lee C, Gianos M, Klausnermyer WB: Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009, 102:179-187.
5. Lenz HJ: Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12:601-609.
6. Sakaeda T, Kadoyama K, Okuno Y: Adverse event profiles of platinum agents: Data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci 2011, 8:487-491.
7. Sakaeda T, Kadoyama K, Yabuuchi H, Niijinuma S, Seki K, Shiraishi Y, Okuno Y: Platinum agent-induced hypersensitivity reactions: Data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2011, 8:332-338.
8. Evans SJ, Waller PC, Davis S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001, 10:483-486.
9. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orr E, Egberts AC: A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002, 11:13-10.
10. Bate A, Lindquist M, Edwards R, Olsson S, Orr E, Lansner A, De Freitas RM: A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998, 54:315-321.
11. Starman A, Machado SG, O’Neill RT: Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf 2002, 25:381-392.
12. Bate A, Evans SJ: Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009, 18:627-636.
13. Gould RJ: Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf 2003, 12:559-574.
14. Almenoff JS, Pattrisswell EN, Gibbs TG, DuMouchel W, Evans SJ, Yuen N: Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007, 82:157-166.
15. Syrigou E, Dannios I, Kattesis E, Makrilla N, Tourkantonis I, Dilana K, Gkiozos I, Saif MM, Syrigos KN: Hypersensitivity reactions to docetaxel: Retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011, 156:320-324.
16. Szebeni J, Muggia FM, Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998, 90:300-306.
17. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, Talmon Y: Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol 2001, 1:721-735.
18. Biswal BM: Anaphylaxis following continuous 5-fluorouracil infusion chemotherapy. Aust N Z J Med 1999, 29:743-744.
19. Sridhar KS: Allergic reaction to 5-fluorouracil infusion. Cancer 1996, 58:862-864.
20. Eppingter T, Serberer K: Desensitization to 5-fluorouracil. Allergy Asthma Proc 1999, 20:189-191.
21. Millà Santos A, Sanchez Medina F: Anaphylactic reaction following iv. administration of 5-fluorouracil. Cancer Treat Rep 1986, 70:1346.
22. Meijs BI, de Waard-van der Spek FB: Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudex cream). Contact Dermatitis 2007, 57:58-60.
23. Epstein E: Does intermittent “pulse” topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998, 38:77-80.
24. Yesudian PD, King CM: Allergic contact dermatitis from stearyl alcohol in Efdex cream. Contact Dermatitis 2001, 45:313-314.
25. Sánchez-Pérez J, Bartolomé B, del Río MJ, García-Díez A: Allergic contact dermatitis from 5-fluorouracil with positive intradermal test and doubtful patch test reactions. Contact Dermatitis 1999, 41:106-107.
26. Degen A, Alter M, Schenck F, Satzger J, Völker B, Kapp A, Gutzmer R: The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 2010, 8:652-661.
27. Yen-Revollo JL, Goldberg RM, McLeod HL: Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008, 14:8-13.
28. Chiara S, Nobile MT, Baracchi C, Sanguineti O, Vincenti M, Di Somma C, Meszaros P, Rosso R: Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997, 33:967-969.

doi:10.1186/1756-9966-30-93
Cite this article as: Kadoyama et al.: Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS. Journal of Experimental & Clinical Cancer Research 2011 30:93.